Abstract

Evaluation of the Stability of Promethazine Hydrochloride in Pluronic Lecithin Organogel and the Determination of an Appropriate Beyond-use Date

Author(s): Peacock Gina F, Sauvageot Jurgita

Issue: Jul/Aug 2014 - Volume 18, Number 4

Page(s): 345-347

Download in electronic PDF format for $75
  • Evaluation of the Stability of Promethazine Hydrochloride in Pluronic Lecithin Organogel and the Determination of an Appropriate Beyond-use Date Page 1
  • Evaluation of the Stability of Promethazine Hydrochloride in Pluronic Lecithin Organogel and the Determination of an Appropriate Beyond-use Date Page 2
  • Evaluation of the Stability of Promethazine Hydrochloride in Pluronic Lecithin Organogel and the Determination of an Appropriate Beyond-use Date Page 3

Abstract

Previous reports indicate that pharmacists are assigning a wide variety of beyond-use dates to extemporaneously compounded medications in topical Pluronic lecithin organogel. The objective of this study was to evaluate the stability of promethazine in Pluronic lecithin organogel over a period of six months and to determine an appropriate beyond-use date. A stability-indicating high-performance liquid chromatography method for promethazine in Pluronic lecithin organogel was validated in our laboratory. Samples of each formulation were analyzed by high-performance liquid chromatography at 0, 7, 14, 21, 28, 45, 60, 90, and 180 days. At each time point, the average concentration and average percent of initial concentration were calculated. The beyond-use date was determined at the time period that the samples were physically stable and maintained at least 90% of the initial concentration. Promethazine hydrochloride was chemically stable in Pluronic lecithin organogel for the period of six months. However, the formulation was physically stable only up to 60 days, and the gel matrix showed signs of physical instability at 90 days, therefore, a 60-day beyond-use date is appropriate for this formulation.

Related Keywords

  • promethazine hydrochloride
  • Pluronic lecithin organogel
  • topical preparations
  • transdermal vehicle
  • stability
  • beyond-use dates
  • formulations

Related Categories

  • EXCIPIENTS
  • PEER-REVIEWED
  • STABILITIES, COMPATIBILITIES
  • DOSAGE FORMS/DRUG CARRIERS
  • NEUROLOGY
  • STORAGE

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy		 Title/Author
(Click for Abstract / Details / Purchase)
Jul/Aug 2014
Pg. 345-347
Evaluation of the Stability of Promethazine Hydrochloride in Pluronic Lecithin Organogel and the Determination of an Appropriate Beyond-use Date
Author(s): Peacock Gina F, Sauvageot Jurgita
May/Jun 2005
Pg. 242-246
Bioavailability of Promethazine in a Topical Pluronic Lecithin Organogel: A Pilot Study
Author(s): Glisson James K, Wood Rebecca L, Kyle Patrick B, Cleary John D
Jul/Aug 2014
Pg. 348-350
Evaluation of the Stability of Ketoprofen in Pluronic Lecithin Organogel and the Determination of an Appropriate Beyond-use Date
Author(s): Peacock Gina F, Sauvageot Jurgita, Addo Richard T
May/Jun 2014
Pg. 253-255
Evaluation of the Stability of Fluoxetine in Pluronic Lecithin Organogel and the Determination of an Appropriate Beyond-use Date
Author(s): Peacock Gina F, Sauvageot Jurgita
May/Jun 2014
Pg. 256-261
Preparation and In Vitro Evaluation of a Pluronic Lecithin Organogel Containing Ricinoleic Acid for Transdermal Delivery
Author(s): Boddu Sai HS, Bonam Sindhu Prabha, Wei Yangjie, Alexander Kenneth
May/Jun 2013
Pg. 247-253
Effect of Formulation pH on Transdermal Penetration of Antiemetics Formulated in Poloxamer Lecithin Organogel
Author(s): Woodall Rachel, Arnold John J, McKay Doug, Abill C Scott
May/Jun 2009
Pg. 245
Oxycodone Hydrochloride 10 mg/mL in Pluronic Lecithin Organogel
Author(s): Allen Loyd V Jr
Jan/Feb 2022
Pg. 65-71
Physical Stability and Release Profile of Compounded Gabapentin Containing Pluronic Lecithin Organogel for Neuropathic Pain Management
Author(s): Hong Eun Ji, Sumanasekera Wasana, Le Uyen Minh
Nov/Dec 2010
Pg. 512
Amitriptyline Hydrochloride 2%, Baclofen 5%, Ketamine Hydrochloride 5%, Ketoprofen 10% in Pluronic Lecithin Organogel
Author(s): Allen Loyd V Jr
Jan/Feb 2012
Pg. 62-63
The Use of Pluronic Lecithin Organogels in the Transdermal Delivery of Drugs
Author(s): Bramwell Bethany L, Williams LaVonn A
Nov/Dec 2010
Pg. 522-525
Stability of Methimazole in Poloxamer Lecithin Organogel to Determine Beyond-Use Date
Author(s): Pignato Alyssa, Pankaskie Marvin, Birnie Christine
Sep/Oct 2012
Pg. 428-430
Evaluation of the Stability of Acetaminophen in Pluronic Lecithin Organogel and the Determination of an Appropriate Beyond-Use Date
Author(s): Peacock Gina F, Sauvageot Jurgita
Jul/Aug 2021
Pg. 322
BHR in PLO Gel (Benadryl, Haldol, and Reglan in Pluronic Lecithin Organogel)
Author(s): Allen Loyd V Jr
Mar/Apr 2004
Pg. 101-105
Pluronic Lecithin Organogel for Local Delivery of Anti-Inflammatory Drugs
Author(s): Frankum James, Ramsay Dale, Das Nandita G, Das Sudip K
May/Jun 2012
Pg. 248-252
In Vitro Percutaneous Absorption of Ketoprofen and Testosterone: Comparison of Pluronic Lecithin Organogel vs. Pentravan Cream
Author(s): Lehman Paul A, Raney Sam G
May/Jun 2009
Pg. 244
Morphine Sulfate 50 mg/mL in Pluronic Lecithin Organogel
Author(s): Allen Loyd V Jr
Nov/Dec 2008
Pg. 540
Cyclobenzaprine Hydrochloride 0.5% and Diclofenac Sodium 3% in Pluronic Lecithin Organogel
Author(s): Allen Loyd V Jr
May/Jun 2009
Pg. 220-221
Promethazine 25 mg/mL in Pluronic Lecithin Organogel for Nausea and Vomiting in a Pediatric Patient: A Case Report
Author(s): Muller George
May/Jun 2003
Pg. 180-183
The History of Pluronic Lecithin Organogel: An Interview With Marty Jones, BSPharm, FACA, FIACP
Author(s): Allen Loyd V Jr
May/Jun 2011
Pg. 245
Ketoprofen 10%, Ibuprofen 10%, Cyclobenzaprine Hydrochloride 2%, and Piroxicam 2% in Pluronic Lecithin Organogel Gel
Author(s): Allen Loyd V Jr